Biopharma · FDA Approvals · Stock

CMPX Compass Therapeutics

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is eng…

Assets on file: tovecimig

Start live analysis of CMPX Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for CMPX, including recently decided ones.

May 2027

May 1, 2027

in 182 days

CMPXCompass Therapeutics

tovecimig: Phase 1/Phase 2 trial NCT06548412 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

August 2027

Aug 2027

Aug 31, 2027

in 304 days

CMPXCompass Therapeutics

tovecimig: Phase 2/Phase 3 trial NCT05506943 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

June 2029

Jun 2029

Jun 30, 2029

in 973 days

CMPXCompass Therapeutics

tovecimig: Phase 1/Phase 2 trial NCT07392957 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

August 2030

Aug 2030

Aug 31, 2030

in 1400 days

CMPXCompass Therapeutics

tovecimig: Phase 2 trial NCT07662031 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Recent first-hand events

Every first-hand event for CMPX, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Sep 22, 2026

12:30 PM

CMPXCompass Therapeutics

Compass Receives FDA Feedback Requiring Survival Trial for Tovecimig BLA in BTC

FDA recommended Compass conduct an additional trial demonstrating survival benefit before submitting a BLA for tovecimig in previously treated advanced BTC. Compass disagrees, citing positive ORR and PFS data from the Phase 2/3 COMPANION-002 study plus unmet need, and plans to engage further with the Agency while preparing the submission.

OtherSEC 8-K Open record

Apr 27, 2026

11:30 AM

CMPXCompass Therapeutics

Compass reports positive Phase 2/3 topline for tovecimig in BTC

COMPANION-002 met its primary ORR endpoint (17.1% vs 5.3%, p=0.031) and showed a statistically significant PFS benefit (4.7 vs 2.6 months, HR=0.44). The company plans to meet with FDA in the coming months to discuss these data ahead of a planned BLA submission.

Topline resultsSEC 8-K Open record1 update